Jayne David R.W. 4/A
4/A · Aurinia Pharmaceuticals Inc. · Filed Jul 11, 2022
Insider Transaction Report
Form 4/AAmended
Jayne David R.W.
Director
Transactions
- Exercise/Conversion
Common Stock
2022-05-18$3.62/sh+10,000$36,200→ 40,000 total - Exercise/Conversion
Stock Option (right to buy)
2022-05-18−10,000→ 0 totalExercise: $3.62Exp: 2027-02-16→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
- [F2]The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.